Cost effectiveness of a potential vaccine for Human papillomavirus

Emerging Infectious Diseases

Volumn 9, Issue 1, 2003, Pages 37-48

  Sanders, Gillian D ^a   Taira, Al V ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CANCER MORTALITY; CANCER RISK; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; INFECTION PREVENTION; LIFE EXPECTANCY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SENSITIVITY ANALYSIS; THEORETICAL MODEL; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VALIDATION PROCESS; VIRUS INFECTION; WART VIRUS;

EID: 0037242467     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0901.020168     Document Type: Article

References (40)

1. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
2. Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, Hsieh CY, et al. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer 1995;62:565-71.
3. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
4. Bergeron C, Barrasso R, Beaudenon S, Flamant P, Croissant O, Orth G. Human papillomaviruses associated with cervical intraepithelial neoplasia. Great diversity and distinct distribution in low- and high-grade lesions. Am J Surg Pathol 1992;16:641-9.
5. Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60.
6. Feoli-Fonseca JC, Oligny LL, Brochu P, Simard P, Falconi S, Yotov WV. Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR-direct sequencing approach. J Med Virol 2001;63:284-92.
7. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
8. Connett H. HPV vaccine moves into late stage trials. Nat Med 2001;7:388.
9. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
10. Schiller J, Lowy D. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001;28:50-4.
11. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
12. Abma JC, Sonenstein FL. Sexual activity and contraceptive practices among teenagers in the United States, 1988 and 1995. Vital Health Stat 23 2001:1-79.
13. Lawrence MH, Goldstein MA. Hepatitis B immunization in adolescents. J Adolesc Health 1995;17:234-43.
14. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263:1218-22.
15. Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995;85:202-10.
16. Melnikow J, Nuovo J, Paliescheskey M. Management choices for patients with squamous atypia on Papanicolaou smear. A toss up? Med Care 1996;34:336-47.
17. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158-71.
18. Schiller JT, Hidesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 2000; 19:67-74.
19. Da Silva DM, Eiben GL, Fausch SC, Wakabayashi MT, Rudolf MP, Velders MP, et al. Cervical cancer vaccines: emerging concepts and developments. J Cell Physiol 2001;186:169-82.
20. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
21. Munoz N, Bosch FX. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Bulletin of the Pan American Health Organization 1996;30:362-77.
22. Stoler MH. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 2000;19:16-28.
23. McCrory DC, Matchar DB, Bastian L, Datta S, Hasselblad V, Hickey J, et al. Evaluation of cervical cytology. Evidence report/technology assessment no. 5. (Prepared by Duke University under Contract No. 290-97-0014.) AHCPR Publication No. 99-E010. Rockville, MD: Agency for Health Care Policy and Research. February 1999.
24. Sawaya GF, Brown AD, Washington AE, Garber AM. Clinical practice. Current approaches to cervical-cancer screening. N Engl J Med 2001;344:1603-7.
25. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.
26. Eddy DM. Screening for cervical cancer. Ann Intern Med 1990;113:214-26.
27. Helms LJ, Melnikow J. Determining costs ofhealth care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment. Med Care 1999;37:652-61.
28. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 1998;339:380-6.
29. Vold Pepper P, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin Infect Dis 2000;30:157-64.
30. Institute of Medicine (U.S.). Committee to Study Priorities for Vaccine Development, Stratton KR, Durch J, Lawrence RS. Vaccines for the 21st century: a tool for decisionmaking. Washington: National Academy Press; 2000.
31. Goldstein ST, Cassidy WM, Hodgson W, Mahoney FJ. Factors associated with student participation in a school-based hepatitis B immunization program. J Sch Health 2001;71:184-7.
32. Hepatitis B vaccination of adolescents - California, Louisiana, and Oregon, 1992-1994. MMWR Morb Mortal Wkly Rep 1994;43:605-9.
33. Wong VK, WoodruffC, Shapiro R. Compliance ofhepatitis B vaccination in patients presenting to a teenage clinic. Pediatr Infect Dis J 1994;13:936.
34. Kollar LM, Rosenthal SL, Biro FM. Hepatitis B vaccine series compliance in adolescents. Pediatr Infect Dis J 1994;13:1006-8.
35. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
36. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986;13(Suppl A):39-45.
37. Report of the Committee on Infectious Diseases. J Clin Neurophysiol 1994;11:128-32.
38. Irwin CE Jr Millstein SG, Ellen JM. Appointment-keeping behavior in adolescents: factors associated with follow-up appointment-keeping. Pediatrics 1993;92:20-3.
39. Oppenheim GL, Bergman JJ, English EC. Failed appointments: a review. J Fam Pract 1979;8:789-96.
40. Simmons AV, Atkinson K, Atkinson P, Crosse B. Failure of patients to attend a medical outpatient clinic. J R Coll Physicians Lond 1997;31:70-3.